Ceftriaxone Dosing in Dialysis Patients
No dose adjustment is required for ceftriaxone in patients undergoing hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (CRRT), and no supplemental dosing is needed after dialysis sessions. 1
Hemodialysis
Standard dosing of ceftriaxone (1-2 g daily) should be maintained without adjustment in hemodialysis patients. The FDA label explicitly states that ceftriaxone is not removed by hemodialysis, and no additional supplementary dosing is required following dialysis 1. This recommendation is supported by pharmacokinetic studies demonstrating:
- Ceftriaxone has a prolonged half-life of approximately 14-16 hours in end-stage renal disease (ESRD) patients during the interdialysis period 2, 3
- Only 41% of plasma concentrations decrease during a 4-hour hemodialysis session, with concentrations remaining well within the therapeutic range (40.4 μg/mL) at the end of dialysis 2
- Hemodialysis clearance is relatively low (26-30 mL/min/m² dialyzer area), insufficient to necessitate dose supplementation 4
The maximum daily dose should not exceed 2 grams in patients with both severe renal and hepatic dysfunction, as ceftriaxone undergoes dual excretion via both renal and biliary routes 1.
Practical Considerations for Hemodialysis
- Administer ceftriaxone at the standard dose (1-2 g) once daily, regardless of dialysis timing 1
- No post-dialysis supplementation is required 1
- Monitor for neurological adverse reactions (encephalopathy, seizures, myoclonus) in patients with severe renal impairment, as overdosage has been reported in this population 1
- Close clinical monitoring for safety and efficacy is advised when both severe renal and hepatic dysfunction coexist 1
Peritoneal Dialysis
Standard ceftriaxone dosing (1-2 g daily) should be used for peritoneal dialysis patients without adjustment. The FDA label confirms that ceftriaxone is not removed by peritoneal dialysis 1. Pharmacokinetic studies demonstrate:
- Peritoneal dialysis does not remove measurable amounts of ceftriaxone from plasma 5
- The kinetic disposition in peritoneal dialysis patients is similar to hemodialysis patients during their interdialysis period 5
- No ceftriaxone was detected in the dialysate of patients on continuous peritoneal dialysis 5
Continuous Renal Replacement Therapy (CRRT)
Standard ceftriaxone dosing (1-2 g daily) is appropriate for patients receiving CRRT, with no dose reduction required. A pharmacokinetic study in patients undergoing continuous veno-venous hemofiltration (CVVH) demonstrated that:
- Pharmacokinetic parameters for renal, nonrenal, and systemic clearance were similar between CVVH patients and those with normal renal function 6
- Drug recovery in the ultrafiltrate with CVVH was comparable to urinary recovery in patients with normal renal function 6
- The sieving coefficient of ceftriaxone (0.69) exceeded the expected free fraction in plasma, but this did not necessitate dose adjustment 6
Key Monitoring Parameters
Monitor patients receiving ceftriaxone during any form of dialysis for:
- Neurological adverse reactions including encephalopathy, seizures, myoclonus, and non-convulsive status epilepticus, particularly in those with severe renal impairment 1
- Prothrombin time alterations, especially in patients with impaired vitamin K synthesis or low vitamin K stores 1
- Signs of gallbladder pseudolithiasis or urolithiasis, which may appear as sonographic abnormalities 1
Critical Caveat
In patients with both severe renal and hepatic dysfunction, the ceftriaxone dose should not exceed 2 grams daily, as the dual excretory pathways are compromised 1. This is the only scenario requiring dose limitation in dialysis patients.